3288 results for «2026年永杉锂业、北方铜业、胜利股份投资价值对比»
3288 results
Mitral Late-Breaking Trials: CLASP IID, AltaValve transseptal programme, MitraSwiss in men and women, MiCLASP...
19 Nov 2023 – From PCR London Valves 2023
Discover the mitral late-breaking trials which were presented during PCR London Valves 2023:
- One-year outcomes of transcatheter mitral repair from the CLASP IID Registry
- AltaValve transseptal programme update
- Mitral TEER in men and women from MitraSwiss registry: is equality achieved?
- Combined impact of mitral valve gradients and mitral regurgitation reduction...
The EVOQUE and PASCAL Precision systems in action: simulation- and case-based learning
20 Nov 2023 – From PCR London Valves 2023
This session explores the features of the PASCAL Precision and the EVOQUE tricuspid replacement systems through simulators and case presentations, while a panel of experts discuss the technology, witnessing live demonstrations of treating mitral and tricuspid regurgitation patients.
Tricuspid Late-Breaking Trials: TRISCEND at 2 years, TEER in primary tricuspid regurgitation, TriCLASP, bRIGHT...
19 Nov 2023 – From PCR London Valves 2023
Discover the tricuspid late-breaking trials which were presented during PCR London Valves 2023:
- TRISCEND study two-year outcomes: transfemoral TTVR
- Transcatheter edge-to-edge repair in patients with primary tricuspid regurgitation
- One-year outcomes of transcatheter tricuspid valve repair from the TriCLASP study
- TTVR with the LuX-Valve system: one-year outcomes of a multicentre experience
- Real-world...
Is only fixing functional mitral regurgitation in heart failure patients enough?
20 Nov 2023 – From PCR London Valves 2023
This session offers insights into combo therapy involving Carillon for patients with functional mitral regurgitation. It covers details of the EMPOWER trial, a double-blinded, sham-controlled study, and explores the potential benefits of early treatment for patients with functional mitral regurgitation.
The Top Late-Breaking Trials: TRISCEND II, TRILUMINATE at 3 years, EuroSMR score, CLASP IID, OPERA-TAVI...
19 Nov 2023 – From PCR London Valves 2023
Discover the top late-breaking trials which were presented during PCR London Valves 2023:
- TRISCEND II: A randomised trial of transcatheter tricuspid valve replacement vs medical therapy
- Percutaneous edge-to-edge repair for tricuspid regurgitation: TRILUMINATE trial three-year outcomes
- Transcatheter mitral valve-in-valve vs. redo surgical replacement for degenerated bioprostheses
- Artificial intelligence derived risk...
Essentials of lifetime management of TAVI patients
20 Nov 2023 – From PCR London Valves 2023
In this session, discover the key features and benefits of next-generation transcatheter heart valve technology. Gain insights into managing bicuspid and valve-in-valve interventions, and understand the procedural and clinical significance of intermediate and XL sizes in addressing unmet clinical needs.
Rapid-fire - LAA closure and plugging
17 Feb 2024 – From PCR Tokyo Valves 2024
In this series of rapid-fire case submissions, explore cases of left atrium appendage closure and plugging. Discover compelling cases such as the transcatheter closure of a very late atrial septal defect device erosion, learn about the importance of transseptal puncture during left appendage closure, and more....
Facilitating coronary access after TAVI
17 Feb 2024 – From PCR Tokyo Valves 2024
What are the challenges in coronary access after TAVI and what techniques may be used to facilitate it? Join this session to learn the answers to that question, as well as gaining insight into how to optimize the coronary access in the index procedure.
The 2024 top Japanese abstracts
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore the most outstanding Japanese abstract submissions from PCR Tokyo Valves 2024, including a study on the effect of chronic kidney disease in clinical outcomes of Japanese patients treated with MitraClip system, and insight into the deformation of transcatheter heart valves with mitral valve-in-valve.
The role of WATCHMAN therapy in optimising results and future perspectives
17 Feb 2024 – From PCR Tokyo Valves 2024
This special session sponsored by Boston Scientific will help you understand the latest status and the value of WATCHMAN therapy, as well as learning about future perspectives of LAA closure by new WATCHMAN FLX pro.
Rapid-fire - Vascular access in TAVI
17 Feb 2024 – From PCR Tokyo Valves 2024
Discover a selection of rapid-fire TAVI vascular access cases: how to deliver a transcatheter heart valve in a calcified aorta, using the buddy wire technique in TAVR with severely tortuous aorta, and more!
Mitral and tricuspid intervention
17 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to discover selected clinical cases regarding complex mitral and tricuspid interventions. Gain insights into phenotypes of secondary tricuspid regurgitation in echocardiography, learn about treatment effectiveness and one-year composite endpoint by clip size of TEER for AFMR, and more!
Rapid-fire - TAVI concomitant with CAD
17 Feb 2024 – From PCR Tokyo Valves 2024
In this series of rapid-fire case submissions, explore cases of TAVI concomitant with coronary artery disease. Learn about innovative procedures such as valve-in-valve chimney stenting, intermediate size THV implantation with coronary protection by chimney stenting, and more!
Tailoring the TEER for an Asian patient
17 Feb 2024 – From PCR Tokyo Valves 2024
In this special session sponsored by Abbott, stay up to date with the latest real-world data from the EXPAND G4 study, understand the challenges that Asian heart anatomy presents for TEER therapy, and learn how the four clip sizes of the G4 MitraClip system can be...
Learn the procedure strategy - Lifetime management of aortic stenosis therapy with self-expandable valve
17 Feb 2024 – From PCR Tokyo Valves 2024
This special session sponsored by Medtronic focuses on learning what characteristic valves should be used to treat aortic stenosis patients with low calcification or with extremely small native aortic annuluses, and what to pay attention to during the procedure.
Structural heart disease care: innovations, teamwork, and patient focus
17 Feb 2024 – From PCR Tokyo Valves 2024
Delivered in Japanese, this session highlights the latest advances in structural heart disease treatment and diagnostics. Learn to understand effective interprofessional collaboration and find out more about patient-centered care excellence!
Selection of the 2024 best clinical cases
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore the most outstanding clinical cases from PCR Tokyo Valves 2024, including a nightmare case with bicuspid aortic valve, pharmaco-invasive management of mechanical valve thrombus with cardiogenic shock, and a TAVR-in-TAVR challenge.
Mitral valve interventions for complex anatomy
17 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session on to learn more about how to manage complex anatomy and complications during mitral valve interventions. Discover compelling cases such as a valve-in-ring TMVR in a fluoroscopically invisible ring, PASCAL for bailout of MitraClip single-leaflet device attachment, and more!
Rapid-fire - Tricuspid valve interventions in various situations
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore a diverse range of tricuspid valve interventions through various rapid-fire case studies. Learn about a successful TEER of torrential pentacuspid tricuspid regurgitation, gain insight into a percutaneous transcatheter balloon valvuloplasty as a bridge therapy for bioprosthetic tricuspid stenosis, and more!
How to optimise lifetime management of TAVI patients with long life expectancy?
17 Feb 2024 – From PCR Tokyo Valves 2024
In this special session sponsored by Abbott, gain insight into how valve design and features may influence clinical outcomes and future interventions. Learn about hemodynamic efficiency of TAVI valves, and understand the factors influencing durability and clinical performance over time.